Mouse Genetics Facility

小鼠遗传学设施于1999年成立，以满足癌症中心日益增长的需求。 研究人员在小鼠模型中进行基因功能分析，并从2005年开始获得癌症中心的支持。 2002.自上次更新以来，该基金更换了领导层，安东尼·卡波比安科博士现在是 该设施的科学主任和姜平博士的设施主任。在这段时间里，研究所 已投资167，450美元用于新的和升级的设备以及翻新的实验室和动物设施空间。 该设施提供高效生产转基因和敲除/敲入（KO/KI）小鼠， 它在胚胎干细胞培养和工程方面提供了独特的资源和专业知识， 癌症中心的研究人员在体内和体外产生癌症的小鼠模型的好处。电流 服务与癌症中心计划的研究目标相一致，包括：（1）生产 通过原核显微注射DNA转基因构建体的转基因小鼠;（2）产生基因靶向的 129和C57 BL小鼠ES细胞克隆;（3）通过显微注射产生嵌合小鼠 基因靶向ES细胞进入囊胚;（4）通过胚胎移植再衍生小鼠品系;和（5）ES细胞 种植和工程。自2006年以来，该设施已生产出15种转基因小鼠， 获得了11个KO/KI小鼠ES细胞克隆，并产生了8个嵌合KO/KI小鼠。此外，本发明还提供了一种方法， 该设施成功地重新衍生了一个工程小鼠品系，并将提供小鼠胚胎 2008年的冷冻保存服务。该机构正在积极与癌症中心的研究人员合作， 利用其小鼠ES细胞技术，目的是利用人类ES细胞作为载体， 疾病特异性细胞谱系作为一种新的人类疾病模型系统。基金未来的目标 资助期间包括为一些难以实现的小鼠品系开发慢病毒介导的转基因。 利用DNA显微注射技术生产，发展四倍体互补作为一种有效的方法 将C57 BL来源的ES细胞注射到囊胚中产生嵌合体，并建立人ES 细胞培养和工程作为常规服务。

The Mouse Genetics Facility was established in 1999 in response to the increasing need of Cancer Center investigators for analysis of gene function in mouse models, and has received Cancer Center support since 2002. Since the last renewal, the Facility has changed leadership, with Dr. Anthony Capobianco now the scientific director of the Facility and Dr. Ping Jiang the facility director. In this funding period, the Institute has invested $167,450 for new and upgraded equipment and renovated laboratory and animal facility space. The Facility provides highly efficient production of both transgenic and knock-out/knock-in (KO/KI) mice, plus it provides a unique resource and expertise in embryonic stem (ES) cell cultivation and engineering, which benefits Cancer Center investigators generating both in vivo and in vitro murine models of cancer. Current services are aligned with the research objectives of the Cancer Center programs and include: (1) production of transgenic mice by pronuclear microinjection of DNA transgene constructs; (2) generation of genetargeted 129 and C57BL mouse ES cell clones; (3) production of chimeric mice derived from microinjection of gene-targeted ES cells into blastocysts; (4) rederivation of mouse lines by embryo transfer; and (5) ES cell cultivation and engineering. Since 2006, the Facility has produced 15 lines of transgenic mice, successfully generated 11 lines of KO/KI mouse ES cell clones, and produced 8 lines of chimeric KO/KI mice. In addition, the Facility successfully rederived a line of an engineered mouse strain and will offer a mouse embryo cryopreservation service in 2008. The Facility is actively collaborating with Cancer Center investigators to utilize its mouse ES cell technology, with the aim of using human ES cells as a vehicle to derive mutant or disease specific cell lineages as a new human disease model system. Goals for the Facility over the next funding period include developing lentiviral mediated transgenesis for some strains of mice that are difficult to produce with DNA microinjection, developing use of tetraploid complementation as an efficient approach to produce chimeras from injections of ES cells of C57BL origin into blastocysts, and establishing human ES cell cultivation and engineering as a routine service.